{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:49:31Z","timestamp":1790675371552,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.lfs.2019.03.053","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T12:05:49Z","timestamp":1553256349000},"page":"120-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"special_numbering":"C","title":["Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment"],"prefix":"10.1016","volume":"224","author":[{"given":"Marika","family":"Premoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Aria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Anna","family":"Bonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Maccarinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gianoncelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Della","family":"Pina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1847-811X","authenticated-orcid":false,"given":"Simone","family":"Tambaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Memo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8862-2896","authenticated-orcid":false,"given":"Andrea","family":"Mastinu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2019.03.053_bb0005","doi-asserted-by":"crossref","unstructured":"Bonini SA, Premoli M, Tambaro S, Kumar A, Maccarinelli G, Memo M, et al. Cannabis sativa: a comprehensive ethnopharmacological review of a medicinal plant with a long history. J. Ethnopharmacol.. 2018;227:300\u201315.","DOI":"10.1016\/j.jep.2018.09.004"},{"key":"10.1016\/j.lfs.2019.03.053_bb0010","doi-asserted-by":"crossref","first-page":"140","DOI":"10.20882\/adicciones.858","article-title":"Psychoactive constituents of cannabis and their clinical implications: a systematic review","volume":"30","author":"Casajuana Koguel","year":"2018","journal-title":"Adicciones"},{"key":"10.1016\/j.lfs.2019.03.053_bb0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/09581596.2015.1038218","article-title":"Human rights, public health and medicinal cannabis use","volume":"26","author":"Bone","year":"2016","journal-title":"Crit. Public Health"},{"key":"10.1016\/j.lfs.2019.03.053_bb0020","doi-asserted-by":"crossref","unstructured":"Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, et al. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology. 2018;235:1923\u201332.","DOI":"10.1007\/s00213-018-4885-9"},{"key":"10.1016\/j.lfs.2019.03.053_bb0025","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/jnen\/nly069","article-title":"Anticonvulsant and neuroprotective effects of cannabidiol during the juvenile period","volume":"77","author":"Friedman","year":"2018","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.lfs.2019.03.053_bb0030","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1111\/bph.14202","article-title":"Cannabidiol exerts antiepileptic effects by restoring hippocampal interneuron functions in a temporal lobe epilepsy model","volume":"175","author":"Khan","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2019.03.053_bb0035","doi-asserted-by":"crossref","unstructured":"Sales AJ, Fogaca MV, Sartim AG, Pereira VS, Wegener G, Guimaraes FS, et al. Cannabidiol induces rapid and sustained antidepressant-like effects through increased BDNF signaling and synaptogenesis in the prefrontal cortex. Mol. Neurobiol.. 2018.","DOI":"10.1007\/s12035-018-1143-4"},{"key":"10.1016\/j.lfs.2019.03.053_bb0040","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1515\/revneuro-2017-0101","article-title":"Cannabidiol effects on prepulse inhibition in nonhuman primates","volume":"1","author":"Saletti","year":"2018","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.lfs.2019.03.053_bb0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.physbeh.2018.12.019","article-title":"Effects of cannabidiol in males and females in two different rat models of depression","volume":"201","author":"Shbiro","year":"2018","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.lfs.2019.03.053_bb0050","doi-asserted-by":"crossref","unstructured":"Solowij N, Broyd SJ, Beale C, Prick JA, Greenwood LM, van Hell H, et al. Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial. Cannabis Cannabinoid Res. 2018;3:21\u201334.","DOI":"10.1089\/can.2017.0043"},{"key":"10.1016\/j.lfs.2019.03.053_bb0055","doi-asserted-by":"crossref","unstructured":"Szaflarski JP, Bebin EM, Comi AM, Patel AD, Joshi C, Checketts D, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results. Epilepsia. 2018;59:1540\u20138.","DOI":"10.1111\/epi.14477"},{"key":"10.1016\/j.lfs.2019.03.053_bb0060","doi-asserted-by":"crossref","unstructured":"Linge R, Jimenez-Sanchez L, Campa L, Pilar-Cuellar F, Vidal R, Pazos A, et al. Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT\/glutamate neurotransmission: role of 5-HT1A receptors. Neuropharmacology. 2016;103:16\u201326.","DOI":"10.1016\/j.neuropharm.2015.12.017"},{"key":"10.1016\/j.lfs.2019.03.053_bb0065","doi-asserted-by":"crossref","unstructured":"Sonego AB, Prado DS, Vale GT, Sepulveda-Diaz JE, Cunha TM, Tirapelli CR, et al. Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARgamma receptors. Brain Behav. Immun.. 2018;74:241\u201351.","DOI":"10.1016\/j.bbi.2018.09.014"},{"key":"10.1016\/j.lfs.2019.03.053_bb0070","doi-asserted-by":"crossref","unstructured":"Kumar A, Premoli M, Aria F, Bonini SA, Maccarinelli G, Gianoncelli A, et al. Cannabimimetic plants: are they new cannabinoidergic modulators? Planta. 2019.","DOI":"10.1007\/s00425-019-03138-x"},{"key":"10.1016\/j.lfs.2019.03.053_bb0075","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1039\/C6NP00074F","article-title":"Phytocannabinoids: a unified critical inventory","volume":"33","author":"Hanus","year":"2016","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.lfs.2019.03.053_bb0080","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1098\/rstb.2011.0382","article-title":"Why do cannabinoid receptors have more than one endogenous ligand?","volume":"367","author":"Di Marzo","year":"2012","journal-title":"Philos. Trans. R. Soc., B"},{"key":"10.1016\/j.lfs.2019.03.053_bb0085","doi-asserted-by":"crossref","unstructured":"Mastinu A, Premoli M, Ferrari-Toninelli G, Tambaro S, Maccarinelli G, Memo M, et al. Cannabinoids in health and disease: pharmacological potential in metabolic syndrome and neuroinflammation. Horm. Mol. Biol. Clin. Invest.. 2018a.","DOI":"10.1515\/hmbci-2018-0013"},{"key":"10.1016\/j.lfs.2019.03.053_bb0090","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrd.2018.115","article-title":"New approaches and challenges to targeting the endocannabinoid system","volume":"17","author":"Di Marzo","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2019.03.053_bb0095","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/aps.2016.149","article-title":"Brain cannabinoid receptor 2: expression, function and modulation","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.lfs.2019.03.053_bb0100","article-title":"Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors","author":"Tham","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2019.03.053_bb0105","doi-asserted-by":"crossref","unstructured":"Martinez-Pinilla E, Varani K, Reyes-Resina I, Angelats E, Vincenzi F, Ferreiro-Vera C, et al. Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors. Front. Pharmacol.. 2017;8:744.","DOI":"10.3389\/fphar.2017.00744"},{"key":"10.1016\/j.lfs.2019.03.053_bb0110","doi-asserted-by":"crossref","unstructured":"Navarro G, Reyes-Resina I, Rivas-Santisteban R, Sanchez de Medina V, Morales P, Casano S, et al. Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB1-CB2 heteroreceptor complexes. Biochem. Pharmacol.. 2018;157:148\u201358.","DOI":"10.1016\/j.bcp.2018.08.046"},{"key":"10.1016\/j.lfs.2019.03.053_bb0115","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Ruiz J, Sagredo O, Pazos MR, Garc\u00eda C, Pertwee R, Mechoulam R, et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br. J. Clin. Pharmacol.. 2013;75:323\u201333.","DOI":"10.1111\/j.1365-2125.2012.04341.x"},{"key":"10.1016\/j.lfs.2019.03.053_bb0120","doi-asserted-by":"crossref","unstructured":"McHugh D, Hu SS, Rimmerman N, Juknat A, Vogel Z, Walker JM, et al. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci.. 2010;11:44.","DOI":"10.1186\/1471-2202-11-44"},{"key":"10.1016\/j.lfs.2019.03.053_bb0125","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.nbd.2013.06.016","article-title":"Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors","volume":"59","author":"Mecha","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.lfs.2019.03.053_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2018.00487","article-title":"Cannabinoid ligands targeting TRP channels","volume":"11","author":"Muller","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.lfs.2019.03.053_bb0135","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","article-title":"Molecular targets of cannabidiol in neurological disorders","volume":"12","author":"Ibeas Bih","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.lfs.2019.03.053_bb0140","doi-asserted-by":"crossref","unstructured":"Lazzari P, Pau A, Tambaro S, Asproni B, Ruiu S, Pinna G, et al. Synthesis and pharmacological evaluation of novel 4-alkyl-5-thien-2\u2032-yl pyrazole carboxamides. Cent. Nerv. Syst. Agents Med. Chem.. 2012;12:254\u201376.","DOI":"10.2174\/187152412803760636"},{"key":"10.1016\/j.lfs.2019.03.053_bb0145","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbr.2010.11.022","article-title":"Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice","volume":"217","author":"Lazzari","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.lfs.2019.03.053_bb0150","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.euroneuro.2017.03.010","article-title":"Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats","volume":"27","author":"Lazzari","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.lfs.2019.03.053_bb0155","doi-asserted-by":"crossref","unstructured":"Manca I, Mastinu A, Olimpieri F, Falzoi M, Sani M, Ruiu S, et al. Novel pyrazole derivatives as neutral CB(1) antagonists with significant activity towards food intake. Eur. J. Med. Chem.. 2013;62:256\u201369.","DOI":"10.1016\/j.ejmech.2012.12.056"},{"key":"10.1016\/j.lfs.2019.03.053_bb0160","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bbr.2012.06.033","article-title":"NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile","volume":"234","author":"Mastinu","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.lfs.2019.03.053_bb0165","doi-asserted-by":"crossref","unstructured":"Mastinu A, Pira M, Pinna GA, Pisu C, Casu MA, Reali R, et al. NESS06SM reduces body weight with an improved profile relative to SR141716A. Pharmacol. Res.. 2013;74:94\u2013108.","DOI":"10.1016\/j.phrs.2013.06.001"},{"key":"10.1016\/j.lfs.2019.03.053_bb0170","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejphar.2014.02.013","article-title":"Evaluation of selective cannabinoid CB(1) and CB(2) receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis","volume":"729","author":"Tambaro","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2019.03.053_bb0175","article-title":"Epilepsy as a neurodevelopmental disorder","volume":"3","author":"Bozzi","year":"2012","journal-title":"Front. Psych."},{"key":"10.1016\/j.lfs.2019.03.053_bb0180","doi-asserted-by":"crossref","unstructured":"Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N. Engl. J. Med.. 2017;376:2011\u201320.","DOI":"10.1056\/NEJMoa1611618"},{"key":"10.1016\/j.lfs.2019.03.053_bb0185","doi-asserted-by":"crossref","unstructured":"Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol.. 2016;15:270\u20138.","DOI":"10.1016\/S1474-4422(15)00379-8"},{"key":"10.1016\/j.lfs.2019.03.053_bb0190","doi-asserted-by":"crossref","unstructured":"Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085\u201396.","DOI":"10.1016\/S0140-6736(18)30136-3"},{"key":"10.1016\/j.lfs.2019.03.053_bb0195","doi-asserted-by":"crossref","unstructured":"Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55:791\u2013802.","DOI":"10.1111\/epi.12631"},{"key":"10.1016\/j.lfs.2019.03.053_bb0200","doi-asserted-by":"crossref","unstructured":"Jones NA, Glyn SE, Akiyama S, Hill TD, Hill AJ, Weston SE, et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure. 2012;21:344\u201352.","DOI":"10.1016\/j.seizure.2012.03.001"},{"key":"10.1016\/j.lfs.2019.03.053_bb0205","doi-asserted-by":"crossref","unstructured":"Berkvens JJ, Veugen I, Veendrick-Meekes MJ, Snoeijen-Schouwenaars FM, Schelhaas HJ, Willemsen MH, et al. Autism and behavior in adult patients with Dravet syndrome (DS). Epilepsy Behav.. 2015;47:11\u20136.","DOI":"10.1016\/j.yebeh.2015.04.057"},{"issue":"Suppl. 2","key":"10.1016\/j.lfs.2019.03.053_bb0210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.02994.x","article-title":"The core Dravet syndrome phenotype","volume":"52","author":"Dravet","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.lfs.2019.03.053_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2014.01.006","article-title":"Strain- and age-dependent hippocampal neuron sodium currents correlate with epilepsy severity in Dravet syndrome mice","volume":"65","author":"Mistry","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.lfs.2019.03.053_bb0220","doi-asserted-by":"crossref","unstructured":"Han S, Tai C, Westenbroek RE, Yu FH, Cheah CS, Potter GB, et al. Autistic-like behaviour in Scn1a +\/\u2212 mice and rescue by enhanced GABA-mediated neurotransmission. Nature. 2012;489:385\u201390.","DOI":"10.1038\/nature11356"},{"key":"10.1016\/j.lfs.2019.03.053_bb0225","doi-asserted-by":"crossref","first-page":"11229","DOI":"10.1073\/pnas.1711351114","article-title":"Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome","volume":"114","author":"Kaplan","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lfs.2019.03.053_bb0230","doi-asserted-by":"crossref","unstructured":"Hurst K, Badgley C, Ellsworth T, Bell S, Friend L, Prince B, et al. A putative lysophosphatidylinositol receptor GPR55 modulates hippocampal synaptic plasticity. Hippocampus. 2017;27:985\u201398.","DOI":"10.1002\/hipo.22747"},{"key":"10.1016\/j.lfs.2019.03.053_bb0235","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1111\/bph.14202","article-title":"Cannabidiol exerts antiepileptic effects by restoring hippocampal interneuron functions in a temporal lobe epilepsy model","volume":"175","author":"Khan","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2019.03.053_bb0240","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/epi.12682","article-title":"Lennox-Gastaut syndrome and phenotype: secondary network epilepsies","volume":"55","author":"Archer","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.lfs.2019.03.053_bb0245","doi-asserted-by":"crossref","unstructured":"Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N. Engl. J. Med.. 2018;378:1888\u201397.","DOI":"10.1056\/NEJMoa1714631"},{"key":"10.1016\/j.lfs.2019.03.053_bb0250","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12264-017-0100-y","article-title":"An overview of autism spectrum disorder, heterogeneity and treatment options","volume":"33","author":"Masi","year":"2017","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.lfs.2019.03.053_bb0255","doi-asserted-by":"crossref","unstructured":"Bonini SA, Mastinu A, Maccarinelli G, Mitola S, Premoli M, La Rosa LR, et al. Cortical structure alterations and social behavior impairment in p50-deficient mice. Cereb. Cortex. 2016;26:2832\u201349.","DOI":"10.1093\/cercor\/bhw037"},{"key":"10.1016\/j.lfs.2019.03.053_bb0260","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.neuropharm.2018.02.007","article-title":"Melanocortin 4 receptor stimulation improves social deficits in mice through oxytocin pathway","volume":"133","author":"Mastinu","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2019.03.053_bb0265","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3390\/ijms18091916","article-title":"The endocannabinoid system and autism spectrum disorders: insights from animal models","volume":"18","author":"Zamberletti","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2019.03.053_bb0270","doi-asserted-by":"crossref","unstructured":"Karhson DS, Krasinska KM, Dallaire JA, Libove RA, Phillips JM, Chien AS, et al. Plasma anandamide concentrations are lower in children with autism spectrum disorder. Mol. Autism. 2018;9:18.","DOI":"10.1186\/s13229-018-0203-y"},{"key":"10.1016\/j.lfs.2019.03.053_bb0275","doi-asserted-by":"crossref","unstructured":"Wei D, Lee D, Cox CD, Karsten CA, Penagarikano O, Geschwind DH, et al. Endocannabinoid signaling mediates oxytocin-driven social reward. Proc. Natl. Acad. Sci. U. S. A.. 2015;112:14084\u20139.","DOI":"10.1073\/pnas.1509795112"},{"key":"10.1016\/j.lfs.2019.03.053_bb0280","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.1523\/JNEUROSCI.0504-08.2008","article-title":"TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons","volume":"28","author":"Qin","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.lfs.2019.03.053_bb0285","doi-asserted-by":"crossref","unstructured":"Siniscalco D, Sapone A, Giordano C, Cirillo A, de Magistris L, Rossi F, et al. Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders. J. Autism Dev. Disord.. 2013;43:2686\u201395.","DOI":"10.1007\/s10803-013-1824-9"},{"key":"10.1016\/j.lfs.2019.03.053_bb0290","first-page":"1","article-title":"Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?","author":"Curran","year":"2018","journal-title":"Psychol. Med."},{"key":"10.1016\/j.lfs.2019.03.053_bb0295","first-page":"130","article-title":"Does cannabidiol protect against adverse psychological effects of THC?","volume":"4","author":"Niesink","year":"2013","journal-title":"Front. Psych."},{"key":"10.1016\/j.lfs.2019.03.053_bb0300","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","article-title":"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders","volume":"367","author":"Campos","year":"2012","journal-title":"Philos. Trans. R. Soc., B"},{"key":"10.1016\/j.lfs.2019.03.053_bb0305","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyu041","article-title":"Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice","volume":"18","author":"Gomes","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.lfs.2019.03.053_bb0310","doi-asserted-by":"crossref","unstructured":"Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry. 2012;2:e94.","DOI":"10.1038\/tp.2012.15"},{"key":"10.1016\/j.lfs.2019.03.053_bb0315","doi-asserted-by":"crossref","unstructured":"McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am. J. Psychiatr.. 2018;175:225\u201331.","DOI":"10.1176\/appi.ajp.2017.17030325"},{"key":"10.1016\/j.lfs.2019.03.053_bb0320","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2019.03.053_bb0325","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.lfs.2019.03.053_bb0330","doi-asserted-by":"crossref","unstructured":"Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimaraes FS, et al. Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front. Pharmacol.. 2017;8:259.","DOI":"10.3389\/fphar.2017.00259"},{"key":"10.1016\/j.lfs.2019.03.053_bb0335","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0269881110389095","article-title":"Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT1A receptors","volume":"26","author":"Gomes","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.lfs.2019.03.053_bb0340","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00213-010-2036-z","article-title":"The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors","volume":"213","author":"Gomes","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.lfs.2019.03.053_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2016.00493","article-title":"Bidirectional effects of cannabidiol on contextual fear memory extinction","volume":"7","author":"Song","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2019.03.053_bb0350","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s11920-015-0564-2","article-title":"Psychopharmacological strategies in the management of posttraumatic stress disorder (PTSD): what have we learned?","volume":"17","author":"Bernardy","year":"2015","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.lfs.2019.03.053_bb0355","doi-asserted-by":"crossref","unstructured":"Forman-Hoffman V, Middleton JC, Feltner C, Gaynes BN, Weber RP, Bann C, et al. Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update. Rockville (MD)2018.","DOI":"10.23970\/AHRQEPCCER207"},{"key":"10.1016\/j.lfs.2019.03.053_bb0360","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jpsychires.2012.08.012","article-title":"Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors","volume":"46","author":"Campos","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.lfs.2019.03.053_bb0365","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1111\/bph.13724","article-title":"Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders","volume":"174","author":"Lee","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2019.03.053_bb0370","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.nlm.2018.02.009","article-title":"Learning and memory is modulated by cannabidiol when administered during trace fear-conditioning","volume":"149","author":"Uhernik","year":"2018","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.lfs.2019.03.053_bb0375","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00213-011-2566-z","article-title":"Anxiogenic-like effects of chronic cannabidiol administration in rats","volume":"221","author":"ElBatsh","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.lfs.2019.03.053_bb0380","doi-asserted-by":"crossref","unstructured":"El-Alfy AT, Ivey K, Robinson K, Ahmed S, Radwan M, Slade D, et al. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol. Biochem. Behav.. 2010;95:434\u201342.","DOI":"10.1016\/j.pbb.2010.03.004"},{"key":"10.1016\/j.lfs.2019.03.053_bb0385","doi-asserted-by":"crossref","unstructured":"de Morais H, Chaves YC, Waltrick APF, Jesus CHA, Genaro K, Crippa JA, et al. Sub-chronic treatment with cannabidiol but not with URB597 induced a mild antidepressant-like effect in diabetic rats. Neurosci. Lett.. 2018;682:62\u20138.","DOI":"10.1016\/j.neulet.2018.06.006"},{"key":"10.1016\/j.lfs.2019.03.053_bb0390","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pnpbp.2015.06.017","article-title":"Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice","volume":"64","author":"Schiavon","year":"2016","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.lfs.2019.03.053_bb0395","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.biopha.2017.12.053","article-title":"Recent advances in the neurobiology and neuropharmacology of Alzheimer's disease","volume":"98","author":"Kumar","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2019.03.053_bb0400","doi-asserted-by":"crossref","unstructured":"Libro R, Diomede F, Scionti D, Piattelli A, Grassi G, Pollastro F, et al. Cannabidiol modulates the expression of Alzheimer's disease-related genes in mesenchymal stem cells. Int. J. Mol. Sci.. 2016;18.","DOI":"10.3390\/ijms18010026"},{"key":"10.1016\/j.lfs.2019.03.053_bb0405","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00020","article-title":"In vivo evidence for therapeutic properties of cannabidiol (CBD) for Alzheimer's disease","volume":"8","author":"Watt","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2019.03.053_bb0410","doi-asserted-by":"crossref","unstructured":"Linden R, Esposito G, Scuderi C, Valenza M, Togna GI, Latina V, et al. Cannabidiol reduces A\u03b2-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR\u03b3 involvement. PLoS One. 2011;6:e28668.","DOI":"10.1371\/journal.pone.0028668"},{"key":"10.1016\/j.lfs.2019.03.053_bb0415","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","article-title":"Epidemiology of Parkinson's disease","volume":"124","author":"Tysnes","year":"2017","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.lfs.2019.03.053_bb0420","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-015-0012-0","article-title":"Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection","volume":"10","author":"More","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.lfs.2019.03.053_bb0425","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00482","article-title":"Cannabidiol as a promising strategy to treat and prevent movement disorders?","volume":"9","author":"Peres","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2019.03.053_bb0430","doi-asserted-by":"crossref","unstructured":"Santos NAG, Martins NM, Sisti FM, Fernandes LS, Ferreira RS, Queiroz RHC, et al. The neuroprotection of cannabidiol against MPP + -induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson's disease. Toxicol. in Vitro. 2015;30:231\u201340.","DOI":"10.1016\/j.tiv.2015.11.004"},{"key":"10.1016\/j.lfs.2019.03.053_bb0435","doi-asserted-by":"crossref","unstructured":"Bhattacharyya S, Wilson R, Appiah-Kusi E, O'Neill A, Brammer M, Perez J, et al. Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis. JAMA Psychiat.. 2018;75:1107.","DOI":"10.1001\/jamapsychiatry.2018.2309"},{"key":"10.1016\/j.lfs.2019.03.053_bb0440","doi-asserted-by":"crossref","unstructured":"Chagas MHN, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, et al. Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. J. Psychopharmacol.. 2014;28:1088\u201398.","DOI":"10.1177\/0269881114550355"},{"key":"10.1016\/j.lfs.2019.03.053_bb0445","doi-asserted-by":"crossref","unstructured":"Almeida V, Levin R, Peres FF, Niigaki ST, Calzavara MB, Zuardi AW, et al. Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2013;41:30\u20135.","DOI":"10.1016\/j.pnpbp.2012.10.024"},{"key":"10.1016\/j.lfs.2019.03.053_bb0450","article-title":"PTSD-like memory generated through enhanced noradrenergic activity is mitigated by a dual step pharmacological intervention targeting its reconsolidation","volume":"18","author":"Gazarini","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.lfs.2019.03.053_bb0455","doi-asserted-by":"crossref","unstructured":"Martin-Moreno AM, Reigada D, Ramirez BG, Mechoulam R, Innamorato N, Cuadrado A, et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol. Pharmacol.. 2011;79:964\u201373.","DOI":"10.1124\/mol.111.071290"},{"key":"10.1016\/j.lfs.2019.03.053_bb9500","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neubiorev.2016.12.033","article-title":"The endocannabinoid system as a target for novel anxiolytic drugs","volume":"76","author":"Patel","year":"2017","journal-title":"Neurosci. Biobehav. Rev."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320519302176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320519302176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:19:48Z","timestamp":1758399588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320519302176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":92,"alternative-id":["S0024320519302176"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2019.03.053","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2019.03.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}